Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Untire: an all-embracing self-management eHealth program to cope with cancer-related fatigue.

Kuiper AJ, Wolvers MDJ, Vonk D, Hagenbeek A.

Ecancermedicalscience. 2018 Mar 20;12:ed81. doi: 10.3332/ecancer.2018.ed81. eCollection 2018.

2.

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D.

Haematologica. 2017 Aug;102(8):1413-1423. doi: 10.3324/haematol.2017.165415. Epub 2017 Apr 14.

3.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

4.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A.

J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28.

PMID:
28029326
5.

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ.

J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.

PMID:
28029309
6.

Costs of haematological disease high and rising.

Green T, Bron D, Chomienne C, de Wit TD, de Haas F, Engert A, Hagenbeek A, Jäger U, MacIntyre E, Muckenthaler MU, Smand C, Sonneveld P.

Lancet Haematol. 2016 Aug;3(8):e353-4. doi: 10.1016/S2352-3026(16)30074-6. Epub 2016 Jul 22. No abstract available.

PMID:
27476782
7.

T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy.

Heijink DM, Kater AP, Hazenberg MD, Hagenbeek A, Kersten MJ.

Neth J Med. 2016 May;74(4):147-51. Review.

8.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

PMID:
25925619
9.

The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium.

Sander B, de Jong D, Rosenwald A, Xie W, Balagué O, Calaminici M, Carreras J, Gaulard P, Gribben J, Hagenbeek A, Kersten MJ, Molina TJ, Lee A, Montes-Moreno S, Ott G, Raemaekers J, Salles G, Sehn L, Thorns C, Wahlin BE, Gascoyne RD, Weller E.

Haematologica. 2014 Apr;99(4):715-25. doi: 10.3324/haematol.2013.095257. Epub 2014 Feb 7.

10.

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.

Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC.

J Clin Pharmacol. 2014 Jul;54(7):818-27. doi: 10.1002/jcph.268. Epub 2014 Jan 28.

PMID:
24443277
11.

Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.

Hagenbeek A.

Transfus Apher Sci. 2013 Aug;49(1):43. doi: 10.1016/j.transci.2013.05.024. Epub 2013 Aug 7. No abstract available.

PMID:
23932512
12.

Age and aging in blood disorders: EHA theme of the year 2013-2014.

Chomienne C, McCann S, Green T, Hagenbeek A, Lacombe C, Guenova M, Roberts I, van der Beek I.

Haematologica. 2013 Jun;98(6):831-2. doi: 10.3324/haematol.2013.090415. No abstract available.

13.

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A.

J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 Apr 1.

PMID:
23547079
14.

C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.

Wouters D, Stephan F, Strengers P, de Haas M, Brouwer C, Hagenbeek A, van Oers MH, Zeerleder S.

Blood. 2013 Feb 14;121(7):1242-4. doi: 10.1182/blood-2012-11-467209. No abstract available.

15.

Quality of life in hematology: European Hematology Association theme of the year...and years to come.

Chomienne C, Guenova M, Hagenbeek A, Lacombe C, McCann S, Salek S, Geissler J, van der Beek I.

Haematologica. 2013 Jan;98(1):2-3. doi: 10.3324/haematol.2012.080796. No abstract available.

16.

Raising hematology's European voice: the importance of calling yourself a hematologist.

de Wit TD, Borkhardt A, Chomienne C, Döhner H, Fibbe WE, Foà R, Hagenbeek A, Skoda RC, Smand CR, Jäger U.

Haematologica. 2012 Apr;97(4):476-8. doi: 10.3324/haematol.2011.057257. No abstract available.

17.

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A; 405 Study Investigators.

Blood. 2012 Apr 19;119(16):3698-704. doi: 10.1182/blood-2011-09-378323. Epub 2012 Mar 2.

18.

Optimising the lymphoma response criteria in the era of targeted therapy.

Younes A, Hagenbeek A, Coiffier B.

Lancet Oncol. 2011 Jul;12(7):616-7. doi: 10.1016/S1470-2045(11)70132-2. Epub 2011 Jun 12. No abstract available.

PMID:
21659000
19.

Novel antibodies against follicular non-Hodgkin's lymphoma.

van Meerten T, Hagenbeek A.

Best Pract Res Clin Haematol. 2011 Jun;24(2):231-56. doi: 10.1016/j.beha.2011.03.002. Epub 2011 May 5. Review.

PMID:
21658621
20.

Preface on follicular non-Hodgkin's lymphoma.

Hagenbeek A.

Best Pract Res Clin Haematol. 2011 Jun;24(2):93. doi: 10.1016/j.beha.2011.03.009. Epub 2011 May 6. No abstract available.

PMID:
21658610
21.

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.

Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E.

Blood. 2011 Jun 30;117(26):7070-8. doi: 10.1182/blood-2011-04-345256. Epub 2011 May 2.

22.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H.

Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20. Erratum in: Lancet. 2011 Apr 2;377(9772):1154.

PMID:
21176949
23.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC.

Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17.

24.

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C.

Leuk Lymphoma. 2010 Aug;51 Suppl 1:20-7. doi: 10.3109/10428194.2010.500047. Review.

PMID:
20815760
25.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A.

J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.

26.

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.

van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA.

J Clin Oncol. 2010 May 1;28(13):2246-52. doi: 10.1200/JCO.2009.25.0852. Epub 2010 Apr 5.

PMID:
20368567
27.

CD20-targeted therapy: the next generation of antibodies.

van Meerten T, Hagenbeek A.

Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007. Review.

PMID:
20350667
28.

Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A.

J Clin Oncol. 2009 Dec 20;27(36):6094-100. doi: 10.1200/JCO.2009.22.6258. Epub 2009 Oct 26.

PMID:
19858392
29.

Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A.

J Nucl Med. 2009 Nov;50(11):1837-43. doi: 10.2967/jnumed.109.067587. Epub 2009 Oct 16.

30.

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M; EORTC-GELA H8 Trial Group.

Lancet Oncol. 2009 Dec;10(12):1160-70. doi: 10.1016/S1470-2045(09)70258-X. Epub 2009 Oct 12.

PMID:
19828373
31.

CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.

van Meerten T, Hagenbeek A.

Neth J Med. 2009 Jul-Aug;67(7):251-9. Review.

32.

Biomarkers and prognosis in malignant lymphomas.

Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G.

Clin Lymphoma Myeloma. 2009 Apr;9(2):160-6. doi: 10.3816/CLM.2009.n.038.

PMID:
19406728
33.

[Allogenic stem cell transplantation in the Netherlands].

Schattenberg AV, Schouten HC, Verdonck LF, Willemze R, van der Lelie J, Huijgens PC, van Imhoff GW, van Biezen A, Brand R, Hagenbeek A, de Witte T, Cornelissen JJ.

Ned Tijdschr Geneeskd. 2009 Feb 28;153(9):380-5. Dutch. No abstract available.

PMID:
19348093
34.

Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?

Hagenbeek A.

J Clin Oncol. 2009 Apr 1;27(10):1540-2. doi: 10.1200/JCO.2008.19.8457. Epub 2009 Mar 2. No abstract available.

PMID:
19255319
35.

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.

de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, de Boer JP, van Glabbeke M.

Haematologica. 2009 Jan;94(1):70-7. doi: 10.3324/haematol.13574. Epub 2008 Dec 4.

36.

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.

van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL.

Br J Haematol. 2009 Feb;144(4):524-30. doi: 10.1111/j.1365-2141.2008.07498.x. Epub 2008 Nov 26.

PMID:
19036081
37.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A.

J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14.

PMID:
18854568
38.

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium).

de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Hagenbeek A, Horning S, Lister A, Raemaekers J, Salles G, Gascoyne RD, Weller E.

J Clin Pathol. 2009 Feb;62(2):128-38. doi: 10.1136/jcp.2008.057257. Epub 2008 Sep 15. Retraction in: J Clin Pathol. 2012 Sep;65(9):861-2.

PMID:
18794197
39.

B-cell involvement in chronic graft-versus-host disease.

Kapur R, Ebeling S, Hagenbeek A.

Haematologica. 2008 Nov;93(11):1702-11. doi: 10.3324/haematol.13311. Epub 2008 Aug 25.

40.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J.

Blood. 2008 Jun 15;111(12):5486-95. doi: 10.1182/blood-2007-10-117671. Epub 2008 Apr 4.

41.

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial.

N Engl J Med. 2007 Nov 8;357(19):1916-27.

42.

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.

de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, Gascoyne RD, Salles G, Weller E; Lunenburg Lymphoma Biomarker Consortium.

J Clin Oncol. 2007 Mar 1;25(7):805-12.

PMID:
17327602
43.

Revised response criteria for malignant lymphoma.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma.

J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.

PMID:
17242396
44.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
45.

Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality.

van Rijn RS, Simonetti ER, Hagenbeek A, Bonyhadi M, Storm G, Martens AC, Ebeling SB.

Exp Hematol. 2007 Jan;35(1):117-27.

PMID:
17198880
46.

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A.

Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27.

47.

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.

Clin Cancer Res. 2006 Jul 1;12(13):4027-35.

48.

Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M.

J Clin Oncol. 2006 Jul 1;24(19):3128-35. Epub 2006 Jun 5.

PMID:
16754934
49.

Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.

Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R.

J Clin Oncol. 2006 Apr 1;24(10):1590-6.

PMID:
16575010
50.

Towards immunogene therapy of hematological malignancies.

Ivanov R, Hagenbeek A, Ebeling S.

Exp Hematol. 2006 Mar;34(3):251-63. Review. No abstract available.

PMID:
16543059

Supplemental Content

Loading ...
Support Center